- Barrons.com•4 hours ago
Gilead Sciences (GILD) has been disappointing investors for nearly two years now, and many are growing impatient for the biotech giant to do something to reverse its fortunes. Part of the problem, of course, is that one of its two big businesses--hepatitis C--is curing patients, which requires very different math than chronic treatments, and no one knows how far sales will fall. In fact, Piper Jaffray's Joshua Schimmer and team are surprised it hasn't happened already: And M&A to the rescue?
- Market Realist•5 hours ago
Gilead's liver disease drugs portfolio includes drugs like Sovaldi, Viread, Harvoni, Hepsera, and Epclusa.
- Market Realist•7 hours ago
Gilead’s (GILD) portfolio includes various drugs for key therapeutic areas including HIV/AIDS, liver disease, oncology, cardiovascular, inflammation, respiratory, and others.
GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||70.14 x 900|
|Ask||70.15 x 500|
|Day's Range||70.02 - 70.99|
|52 Week Range||65.38 - 103.10|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||7.06|
|Dividend & Yield||2.08 (2.95%)|
|1y Target Est||N/A|